CAN CLINICAL, BIOLOGICAL OR PHARMACOLOGICAL MARKERS PREDICT SUSTAINED RESPONSE TO INFLIXIMAB? A RETROSPECTIVE ANALYSIS OF ACCENT 1

(1) Janssen Biologics BV

(2) University of Chicago

(3) Centocor Orthobiotech Inc.

(4) Centocor Research & Development, Inc.

(5) University Hospital Gasthuisberg



This item was part of the IBD II session at UEG Week Stockholm 2011

This item can be cited as: Gut 2011; 60 (Suppl 3) A296

You may be interested in:

New drugs about to hit the clinic
English, Presentation, Clinical aspects, Medical management, Colon, Inflammatory bowel disease, 2010

Categorisation:

  • Format
    • Abstract
  • Language
    • English
  • Year
    • 2011